Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
28
05
2023
medline:
28
11
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
The effectiveness of biologic treatments in slowing the progression of psoriatic arthritis is well established, but there is limited and conflicting evidence on their ability to prevent the development of psoriatic arthritis in patients with psoriasis. The objective of this review was to evaluate the role of biologic treatment for psoriasis in preventing or delaying subsequent psoriatic arthritis. A literature search was performed using MEDLINE (PubMed), Embase, Web of Science, and the Cochrane Library for studies published in English from database inception to March 2022 that statistically compared the risk of psoriatic arthritis in patients aged > 16 years who were previously treated with biologic disease-modifying antirheumatic drugs or with other drugs for skin psoriasis. Four articles were eligible for analysis, all retrospective cohort studies. Three were conducted in preselected patients attending dermatology or dermatology-rheumatology collaboration centers and one was a large population-based study. In three studies, a primary two-step statistical analysis yielded a significantly lower risk of psoriatic arthritis in patients treated with biologic agents. These findings were not supported by the large retrospective electronic health record-based study. Biologic treatments may be effective in preventing the development of psoriatic arthritis in patients with psoriasis. More research is needed given the retrospective cohort design of all studies included in the review limiting the generalizability of the results, and the conflicting results from the registry study. At present, biologic agents should not be prescribed to unselected patients with psoriasis for the sole purpose of preventing psoriatic arthritis.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The effectiveness of biologic treatments in slowing the progression of psoriatic arthritis is well established, but there is limited and conflicting evidence on their ability to prevent the development of psoriatic arthritis in patients with psoriasis. The objective of this review was to evaluate the role of biologic treatment for psoriasis in preventing or delaying subsequent psoriatic arthritis.
METHODS
METHODS
A literature search was performed using MEDLINE (PubMed), Embase, Web of Science, and the Cochrane Library for studies published in English from database inception to March 2022 that statistically compared the risk of psoriatic arthritis in patients aged > 16 years who were previously treated with biologic disease-modifying antirheumatic drugs or with other drugs for skin psoriasis.
RESULTS
RESULTS
Four articles were eligible for analysis, all retrospective cohort studies. Three were conducted in preselected patients attending dermatology or dermatology-rheumatology collaboration centers and one was a large population-based study. In three studies, a primary two-step statistical analysis yielded a significantly lower risk of psoriatic arthritis in patients treated with biologic agents. These findings were not supported by the large retrospective electronic health record-based study.
CONCLUSIONS
CONCLUSIONS
Biologic treatments may be effective in preventing the development of psoriatic arthritis in patients with psoriasis. More research is needed given the retrospective cohort design of all studies included in the review limiting the generalizability of the results, and the conflicting results from the registry study. At present, biologic agents should not be prescribed to unselected patients with psoriasis for the sole purpose of preventing psoriatic arthritis.
Identifiants
pubmed: 37341960
doi: 10.1007/s40257-023-00801-8
pii: 10.1007/s40257-023-00801-8
doi:
Substances chimiques
Biological Factors
0
Biological Products
0
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
865-873Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339 .
doi: 10.1038/jid.2012.339
pubmed: 23014338
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70. https://doi.org/10.1056/NEJMra1505557 .
doi: 10.1056/NEJMra1505557
pubmed: 28273019
Zabotti A, De Lucia O, Sakellariou G, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519–34. https://doi.org/10.1007/s40744-021-00378-w .
doi: 10.1007/s40744-021-00378-w
pubmed: 34596875
pmcid: 8572278
Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915–23. https://doi.org/10.1002/art.39494 .
doi: 10.1002/art.39494
Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–9. https://doi.org/10.1002/art.24172 .
doi: 10.1002/art.24172
pubmed: 19177544
pmcid: 3061343
Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52:568–75. https://doi.org/10.1093/rheumatology/kes324 .
doi: 10.1093/rheumatology/kes324
pubmed: 23221331
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–41. https://doi.org/10.1007/s40265-014-0191-y .
doi: 10.1007/s40265-014-0191-y
pubmed: 24566842
pmcid: 3958815
Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol. 2003;49:S125–32. https://doi.org/10.1016/s0190-9622(03)01145-9 .
doi: 10.1016/s0190-9622(03)01145-9
pubmed: 12894136
Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2014;73:414–9. https://doi.org/10.1136/annrheumdis-2012-202641 .
doi: 10.1136/annrheumdis-2012-202641
pubmed: 23355079
Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):723–38. https://doi.org/10.1016/j.rdc.2015.07.010 .
doi: 10.1016/j.rdc.2015.07.010
Taylor W, Gladman D, Helliwell P, et al. CASPAR study group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. https://doi.org/10.1002/art.21972 .
doi: 10.1002/art.21972
pubmed: 16871531
Robinson JK, Dellavalle RP, Bigby M, et al. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144(1):97–9. https://doi.org/10.1001/archdermatol.2007.28 .
doi: 10.1001/archdermatol.2007.28
pubmed: 18209174
Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–9. https://doi.org/10.1136/annrheumdis-2021-220865 .
doi: 10.1136/annrheumdis-2021-220865
pubmed: 34281904
Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73. https://doi.org/10.1136/annrheumdis-2021-219961 .
doi: 10.1136/annrheumdis-2021-219961
pubmed: 34144965
Rosenthal YS, Schwartz N, Sagy I, et al. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheum. 2022;74(2):237–43. https://doi.org/10.1002/art.41946 .
doi: 10.1002/art.41946
Meer E, Merola JF, Fitzsimmons R, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80–6. https://doi.org/10.1136/annrheumdis-2021-220761 .
doi: 10.1136/annrheumdis-2021-220761
pubmed: 34615637
Lindberg I, Lilja M, Geale K, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in Swedish routine clinical care. Acta Derm Venereol. 2020;100(18):adv00324. https://doi.org/10.2340/00015555-3682 .
doi: 10.2340/00015555-3682
pubmed: 33135771
Merola JF, Tian H, Patil D, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health. J Am Acad Dermatol. 2022;86(4):748–57. https://doi.org/10.1016/j.jaad.2021.09.019 .
doi: 10.1016/j.jaad.2021.09.019
pubmed: 34547358
Chen M, Dai SM. Biologic treatment for psoriasis is unlikely to facilitate psoriatic arthritis development. J Am Acad Dermatol. 2023;88(1):e57–8. https://doi.org/10.1016/j.jaad.2022.09.044 .
doi: 10.1016/j.jaad.2022.09.044
pubmed: 36202144
Soleymani T, Reddy SM, Cohen JM, et al. Early recognition and treatment heralds optimal outcomes: the benefits of combined rheumatology-dermatology clinics and integrative care of psoriasis and psoriatic arthritis patients. Curr Rheumatol Rep. 2017;20(1):1. https://doi.org/10.1007/s11926-017-0706-0 .
doi: 10.1007/s11926-017-0706-0
pubmed: 29185062
Lubrano E, Delle Sedie A, Romanelli M, et al. Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. 2021;40(6):2251–62. https://doi.org/10.1007/s10067-020-05482-w .
doi: 10.1007/s10067-020-05482-w
pubmed: 33155160
Honeyford K, Expert P, Mendelsohn E, et al. Challenges and recommendations for high quality research using electronic health records. Front Digit Health. 2022;9(4): 940330. https://doi.org/10.3389/fdgth.2022.940330 .
doi: 10.3389/fdgth.2022.940330
Shah JR, Murtaza MB, Opara E. Electronic health records: challenges and opportunities. J Int Technol Inform Manage. 2014;23(3):Article 10.